NCT01026974View on ClinicalTrials.gov

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

May 31, 2012

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

rMenB

BIOLOGICAL

rMenB+OMV NZ

Trial Locations (1)

OX3 7LJ

Oxford Vaccine Group, Center for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY